BioPalace
MMXXVI · No. 01
White paper № 01 · 42 pp
The strategic guide to royalty financing in biopharma.
Fig. 01 · Royalty cash flows over time · Illustrative
Industry briefing — open access42 pp · PDF
Deal-by-deal access to overlooked biotech royalties.
Designed for qualified investors
Access curated biotech royalty opportunities, deal by deal.
Request early access
Get early access to healthcare royalty opportunities.
Qualified investors only.
Selling or advising on a royalty?
Submit your opportunity for review.
Curated
High-quality royalty opportunities
Deal-by-deal
Investor access to individual deals
Independent
Rigorous diligence process
No blind pool
No fund commitment or capital deployment
Our Thesis
BioPalace is a syndicate platform, not a fund. We exist to make overlooked biotech royalties investable: underwriting, structuring, and syndicating opportunities that are too specialized for megacap funds but too valuable to remain illiquid.
§ 03Insights · Research deskPaper № 01
§Free download
A note from our research desk.
What makes a royalty deal worth underwriting, and what makes one walk away. Forty-two pages of frameworks, comparables, and cautionary tales from our own pipeline.
Featured Offerings · Q2 2026
Currently in market.
Grade AOpen
Ophthalmic therapy royalty
Approved 2024 · 12-yr term
Asking
$8.4M
IRR
14.2%
62% committed · 14 days left
Grade AOpen
Oncology therapy royalty
Approved 2022 · 14-yr term
Asking
$22M
IRR
12.8%
28% committed · 32 days left
Grade BDiligence
Cardiovascular therapy royalty
Phase III readout pending · 16-yr potential term
Indicative
$3.6M
Target IRR
18.5%
Pre-launch · Q3 listing
Illustrative listings. Full diligence packages disclosed only to verified investors.
§ 02How it works · Diligence architectureFive rounds
Five rounds before a deal lists.
Many marketplaces emphasize access. BioPalace emphasizes selectivity, diligence, and transaction quality. Only a small percentage of reviewed opportunities are expected to reach the BioPalace investor network.
Selective by design · Rolling review
- I.
Sourcing
Direct from biotechs, university tech transfer offices, and inventors. The starting universe is the people closest to the molecule, not corporate intermediaries or brokered packages.
Origin · Field - II.
Financial
Historical receipts confirmed against payor statements. Forward forecast is conservative, transparent, and benchmarked against comparable precedent transactions in the same therapeutic area.
Cashflow · Audit - III.
Scientific
Clinical positioning, label durability, generic and biosimilar entry timing, and competitive set. Reviewed by physicians and scientific advisors with field experience.
Clinical · KOL - IV.
Legal
Ownership chain, scope of rights, transferability, and payor relationship reviewed end to end. Reviewed by clean-room counsel, not relationship counsel.
Title · IP - V.
Verification grade
Only Grade A and Grade B opportunities reach investors. Anything below the bar is rejected, with feedback to the seller. We do not list to bulk up the marketplace.
Listing · Syndicate
§About BioPalace
Built for both sides of the royalty table.
For Investors
Get rewarded for fueling medical innovation.
Curated biotech royalties give you stable income, low correlation to public markets, and the satisfaction of capital that does work in the world. We do the hunting, vetting, and structuring — you allocate.
- 01
Real, measurable patient impact
Every dollar deployed funds a therapy already shipping or on the cusp of approval — not a research stage that may never reach a patient.
- 02
White-glove support
A dedicated investor relations desk, plain-English diligence summaries, and quarterly performance reviews from the people who underwrote your deal.
- 03
Exclusive, curated investments
We see hundreds of opportunities a year. We bring you the few that survive legal, financial, and scientific scrutiny.
Minimum check size disclosed in the deal room. Accredited investors only.
Request investor accessFor Issuers
Flexible, non dilutive funding for innovators.
Monetize your royalties without dilution or loss of control. Reach out to see how we can help fund your next milestone — term sheet to wire in weeks, not quarters.
- 01
Fast capital access
Term sheet to wire in weeks. We bring decisive capital to milestones that won't wait.
- 02
Tailored structuring
Synthetic, traditional, capped, tiered — we build the structure your science and balance sheet need.
- 03
Fair valuation, trusted expertise
Our team has structured billions in royalty transactions across oncology, immunology, metabolic and rare disease.
Reply within one business day. NDA available on request.
Submit a royalty§For Issuers
Unlock your royalties & accelerate funding.
Monetize your royalties without giving up control of your science. Reach out to see how we can help fund your next milestone.
01
Fast capital access
Term sheet to wire in weeks. Decisive capital to milestones that won't wait.
02
Tailored structuring
Synthetic, traditional, capped, tiered — built around your science and balance sheet.
03
Fair valuation
We benchmark against the market and reward strength. No haircuts for opacity.
04
Trusted expertise
Billions structured across oncology, immunology, metabolic and rare disease.
The power of
royalty investing.
Six reasons institutional capital has quietly favored this asset class for decades — now available to qualified investors through a curated, syndicated channel.
- I.
Stable income from sales
Royalties pay as products sell, providing potential for regular cash flow — typically on a quarterly schedule.
- II.
Uncorrelated returns
Cash flows track drug sales and pricing, not equity markets. A cleaner diversifier in a portfolio that already holds public stocks.
- III.
Attractive risk profile
Terms are defined up front. Exposure centers on demand and patent life — not company budgets or quarterly earnings.
- IV.
Social impact
Your capital supports therapies that improve patients' lives. You are rewarded with returns and the satisfaction of doing real work.
- V.
Inflation & bankruptcy protection
Royalties are paid as a percentage of sales — they can rise with prices and may continue through restructurings.
- VI.
Expert diligence
Every opportunity on the platform is independently reviewed by physicians, attorneys, and clinical key opinion leaders before it reaches you.
Leadership
Meet our team.
A team that has structured biopharma transactions, advised on global health policy, and treated patients in the clinic.
Healthcare investment banker and private equity investor with over seven years across biotech royalty investing, growth equity, and biotechnology investment banking.
- Former biotech investment banker at Wells Fargo (San Francisco), with transaction experience spanning public equity raises and M&A transactions.
- Chief Business Officer of the Robert F. Kennedy Medical Center.
- Prior investment roles at Cedar Crest Capital and Eagle Rock Capital.
Education
B.S., University of Southern California, Marshall School of Business
Life sciences strategist with 15+ years across clinical medicine, global health economics, and life sciences corporate strategy.
- Former Partner and Head of Strategy, Pharmaceuticals at IBM — advising C-suite leaders at global pharma on growth, diligence, and royalty financing.
- Former senior economist and diplomat focused on health and pharmaceuticals at the World Bank, PwC, and Oxfam.
Education
M.D., Russian State Medical University · Diploma in Finance, Yale University · M.A. Health Economics, London School of Hygiene & Tropical Medicine
Maly HassanMD
Advisor
Physician and medical advisor with experience across pulmonary medicine, critical care, internal medicine, and healthcare innovation.
- Resident at Emory University — combining clinical practice with strategy, democratizing royalty investing, and relationship building.
- Medical Student Society Leadership and Pediatrics Research at AUBMC.
Education
M.D., American University of Beirut · B.S. Biology, American University of Beirut
In the press
We created BioPalace to support the companies doing some of the hardest, most important work in medicine.
Husein HassanFounder and CEO
As featured in BioSpaceJune 2, 2025Become an Investor
Become an investor today.
Start building wealth and advancing health. Get alerts when new offerings open, and track distributions in your dashboard.